Molecular Templates, Inc. (MTEM): Price and Financial Metrics


Molecular Templates, Inc. (MTEM): $0.51

-0.03 (-6.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MTEM POWR Grades

  • Sentiment is the dimension where MTEM ranks best; there it ranks ahead of 89.48% of US stocks.
  • The strongest trend for MTEM is in Growth, which has been heading down over the past 81 days.
  • MTEM ranks lowest in Momentum; there it ranks in the 7th percentile.

MTEM Stock Summary

  • MTEM has a higher market value than only 10.34% of US stocks; more precisely, its current market capitalization is $33,529,230.
  • The capital turnover (annual revenue relative to shareholder's equity) for MTEM is 8.46 -- better than 95.84% of US stocks.
  • In terms of volatility of its share price, MTEM is more volatile than 96.57% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to MOLECULAR TEMPLATES INC, a group of peers worth examining would be SELB, RXDX, PLRX, RAPT, and TSVT.
  • Visit MTEM's SEC page to see the company's official filings. To visit the company's web site, go to www.mtem.com.

MTEM Valuation Summary

  • In comparison to the median Healthcare stock, MTEM's price/sales ratio is 55% lower, now standing at 0.9.
  • Over the past 217 months, MTEM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MTEM.

Stock Date P/S P/B P/E EV/EBIT
MTEM 2022-11-25 0.9 8.0 -0.4 -0.8
MTEM 2022-11-23 1.0 8.2 -0.4 -0.8
MTEM 2022-11-22 1.0 8.5 -0.4 -0.8
MTEM 2022-11-21 0.9 7.7 -0.4 -0.8
MTEM 2022-11-18 1.0 8.1 -0.4 -0.8
MTEM 2022-11-17 0.9 7.7 -0.4 -0.8

MTEM Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -48.3%.
  • Its 4 year net cashflow from operations growth rate is now at -29.16%.
  • Its 3 year net cashflow from operations growth rate is now at -1453.07%.
MTEM's revenue has moved up $31,790,000 over the prior 52 months.

The table below shows MTEM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 35.107 -93.053 -80.912
2022-06-30 33.246 -93.436 -86.661
2022-03-31 43.963 -100.297 -77.842
2021-12-31 38.697 -30.387 -83.009
2021-09-30 24.23 -29.432 -101.211
2021-06-30 26.149 -24.44 -94.049

MTEM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MTEM has a Quality Grade of C, ranking ahead of 37.75% of graded US stocks.
  • MTEM's asset turnover comes in at 0.13 -- ranking 237th of 681 Pharmaceutical Products stocks.
  • AGEN, ARDX, and LGND are the stocks whose asset turnover ratios are most correlated with MTEM.

The table below shows MTEM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.130 1 -0.688
2021-03-31 0.102 1 -1.004
2020-12-31 0.123 1 -0.976
2020-09-30 0.133 1 -0.940
2020-06-30 0.146 1 -1.283
2020-03-31 0.139 1 -1.005

MTEM Price Target

For more insight on analysts targets of MTEM, see our MTEM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.43 Average Broker Recommendation 1.33 (Strong Buy)

MTEM Stock Price Chart Interactive Chart >

Price chart for MTEM

MTEM Price/Volume Stats

Current price $0.51 52-week high $4.45
Prev. close $0.54 52-week low $0.48
Day low $0.50 Volume 271,262
Day high $0.54 Avg. volume 201,480
50-day MA $0.63 Dividend yield N/A
200-day MA $1.27 Market Cap 28.65M

Molecular Templates, Inc. (MTEM) Company Bio


Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.


MTEM Latest News Stream


Event/Time News Detail
Loading, please wait...

MTEM Latest Social Stream


Loading social stream, please wait...

View Full MTEM Social Stream

Latest MTEM News From Around the Web

Below are the latest news stories about MOLECULAR TEMPLATES INC that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that CEO, Eric Poma, Ph.D., will present a virtual fireside chat at Evercore ISI’s 5th Annual HealthCONx conference which will take place November 29 – December 1, 2022, and an in-person fireside

Yahoo | November 23, 2022

Molecular Templates Third Quarter 2022 Earnings: Beats Expectations

Molecular Templates ( NASDAQ:MTEM ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.24m (up 78% from 3Q...

Yahoo | November 13, 2022

Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases, today reported financial results and business updates for the third quarter of 2022. “We are ex

Yahoo | November 10, 2022

Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will

Yahoo | November 4, 2022

Read More 'MTEM' Stories Here

MTEM Price Returns

1-mo -13.01%
3-mo -27.71%
6-mo -47.57%
1-year -88.36%
3-year -95.72%
5-year -93.80%
YTD -86.99%
2021 -58.25%
2020 -32.86%
2019 246.16%
2018 -59.68%
2017 107.02%

Continue Researching MTEM

Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:

Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.776 seconds.